Navigation Links
Ceragenix Compound Shows Promise for Treating Lethal Cystic,Fibrosis Infections

DENVER--(BUSINESS WIRE)--Jul 2, 2007 - Ceragenix Pharmaceuticals, Inc. (OTCBB:CGXP), a biopharmaceutical company focused on infectious disease and dermatology, today announced that researchers at the University of Pennsylvania led by Dr. Paul Janmey and Dr. Robert Bucki, in collaboration with Dr. Paul B. Savage of Brigham Young University, have demonstrated in a series of in vitro experiments that an investigational drug compound known as CSA-13 shows promise as a potential therapy to treat multidrug resistant Pseudomonas aeuroginosa infections which are a leading cause of morbidity and mortality in patients with cystic fibrosis. The research appears ahead of print in an advanced online publication of the Journal of Antimicrobial Chemotherapy, the official journal of the British Society for Antimicrobial Chemotherapy.

In the reported research, Dr. Bucki and his colleagues evaluated the activity of a CSA-13, a member of the family of Ceragenin(TM) compounds being developed by Ceragenix. CSA-13 is a synthetic non-peptide mimic of the naturally occurring antimicrobial peptide found in the lung. The researchers found that CSA-13:

-- Is significantly more effective than positively charged antibacterial peptides (LL-37) against a multidrug resistant strain of Pseudomonas aeuroginosa;

-- Is far less susceptible to inactivation by negatively charged components found in the sputa of cystic fibrosis patients (DNA and F-actin); and that

-- Is potent even in cystic fibrosis sputum thereby suggesting potential for therapeutic use.

"This new compound has the potential to be a significant advance in the treatment of patients with cystic fibrosis and other lung infections," says senior author Robert Bucki, a Senior Investigator at the University of Pennsylvania's Institute for Medicine and Engineering.

Normal healthy lungs are protected against bacterial infection by the presence of naturally
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Ceragenix Announces Results from Phase IV Study of EpiCeram Meet All Primary and Secondary Endpoints
2. Ceragenix Announces New Publication of Scientific Research on Ceragenin Technology
3. Ceragenix Announces Ceragenins Virtually Prevent Catheter Biofilm Formation in 21 Day Study
4. Neurogen Proprietary Insomnia Compound Data for Two Studies Presented at Associated Professional Sleep Societies Annual Meeting
5. Neurogen Proprietary Insomnia Compound Data Presented at Associated Professional Sleep Societies Annual Meeting
6. Anacor Clinical Study of AN2728, a Novel Anti-Inflammatory Compound, Shows Efficacy in Psoriasis
7. AEterna Zentaris Partner Keryx Presents Phase 1 and Phase 2 Results for Anti-Cancer Compound Perifosine at ASCO Meeting
8. Six Abstracts Featuring Exelixis Compounds Accepted At ASCO Conference
9. ImmunoGen, Inc. Announces Clinical Findings for Three TAP Compounds for Solid Tumors Are to be Reported at ASCO
10. Neurogen Proprietary Insomnia Compound Data Presented at American Psychiatric Association Annual Meeting
11. Microbia Announces Positive Phase 2 Results for Its Investigational Compound Linaclotide
Post Your Comments:
(Date:8/29/2014)... , Aug. 29, 2014 Medina Medical announced ... and member of the Board of Directors on August ... device development and commercialization experience, including over a decade ... previously served as a Partner of the medical device ... CEO of two Foundry start-ups. Mr. Engelson previously served ...
(Date:8/29/2014)... DUBLIN , Aug. 29, 2014 ... the "Global Peptide Cancer Therapeutics Market & Pipeline ... The conventional methods developed to prevent and eradicate ... cancer treatment. These methods are confined to low specificity, ... the researchers to look for a better solution. It ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Development Trend Forecast of Pharmaceutical Equipment Market in China, ... Research and Development Trend Forecast of Pharmaceutical Equipment Market ... China,s pharmaceutical equipment industry in ... competition landscape, and business performance of domestic major enterprises, ...
Breaking Medicine Technology:Medina Medical Announces Erik T. Engelson Joins as Chief Executive Officer 2Global Peptide Cancer Therapeutics Market & Pipeline Insight 2014 2Research and Development Trend Forecast of Pharmaceutical Equipment Market in China, 2014-2018 2
(Date:8/31/2014)... 01, 2014 Recently, BambooIndustry.com, one of the ... with a new selection of bamboo veneers . Additionally, ... percent off) for these high quality products. The promotion will ... senior spokesman says that its top quality veneers are hot ... the new designs of bamboo veneers. All these items are ...
(Date:8/31/2014)... With years of hard work, Delta has now become ... Recently, the company has updated its wheel loader ... All these items are guaranteed to be great. Additionally, they ... It is true that all items in Delta’s used ... specialists. The firm is making full efforts to help worldwide ...
(Date:8/31/2014)... 31, 2014 Asked to offer ... between "Bioavailability" and "absorption," Dr. Priya Khan, Director ... great interest. "Bioavailability" and "absorption" are possibly ... the supplement industry, second perhaps only to the ... and absorption, while related, are not the same. ...
(Date:8/31/2014)... Ticket Down is a dependable source ... Goods Park in suburban Denver. The Mexican national ... other international teams on USA soil. , ... soccer coach aboard, Miguel Herrera, and he has had excellent ... World Cup in Brazil, the Mexican team played quite well ...
(Date:8/31/2014)... (PRWEB) September 01, 2014 Market ... System Industry, 2009-2019 is a professional and in-depth ... System industry. The report firstly reviews the basic ... application and manufacturing technology. , The report then ... Harvesting System listing their product specification, capacity, production ...
Breaking Medicine News(10 mins):Health News:High Quality Bamboo Veneers from Bambooindustry.com Receive International Attention 2Health News:Delta Updates Its Wheel Loader Assortment With A Lot Of Cheap Used Cat 966 Loaders 2Health News:Bioavailability Vs Absorption - NutriGold Publishes Tips to Help Consumers Make Informed Decisions for Their Health 2Health News:Bioavailability Vs Absorption - NutriGold Publishes Tips to Help Consumers Make Informed Decisions for Their Health 3Health News:Bioavailability Vs Absorption - NutriGold Publishes Tips to Help Consumers Make Informed Decisions for Their Health 4Health News:Mexico vs. Bolivia Tickets at Dick’s Sporting Goods Park in Commerce City (Denver), CO: Ticket Down Slashes Ticket Prices on Mexico vs. Bolivia Exhibition Game 2Health News:Mexico vs. Bolivia Tickets at Dick’s Sporting Goods Park in Commerce City (Denver), CO: Ticket Down Slashes Ticket Prices on Mexico vs. Bolivia Exhibition Game 3Health News:Cell Harvesting System Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 2Health News:Cell Harvesting System Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 3Health News:Cell Harvesting System Industry for Global and Chinese Market Forecasts to 2019 in New Research Report Available at ReportsnReports.com 4
... The following is a statement of Matthew L. ... http://www.newscom.com/cgi-bin/prnh/20080918/CFTFKLOGO )The Campaign for Tobacco-Free ... his leadership role in Senate committee approval of ... Administration (FDA) regulatory authority over tobacco products, including ...
... a statement of Matthew L. Myers, President, Campaign ... ) The Campaign for Tobacco-Free Kids applauds ... role in Senate committee approval of legislation that ... regulatory authority over tobacco products, including the authority ...
... of Clinical Oncology. , ... Evanston, IL (Vocus) May 20, 2009 -- ... David J. Winchester , FACS, M.D., Chief of General Surgery and Surgical ... cancer has spread to the lymph nodes may not need a ...
... Alan B. Miller to Retain Chairman and CEO Positions Michael ... Pa., May 20 The Board of Directors of Universal ... nation,s largest hospital companies, today announced the election of Marc ... of Universal Health Service,s Chairman and Chief Executive, Alan Miller, ...
... On May 20, 2009, the US District Court for the ... AZN ) for an injunction barring Apotex (Apotex, ... AstraZeneca,s PULMICORT RESPULES (budesonide inhalation suspension) in the US. ... March 30, 2009, the US Food and Drug Administration granted ...
... SCHAUMBURG, Ill., May 20 Sagent Pharmaceuticals, Inc., ... it has raised $30 million in a second ... strategic investors. The round was again led by ... support upcoming product launches, development activities and strategic ...
Cached Medicine News:Health News:Sen. Jeff Merkley Votes to Protect America's Kids From Tobacco 2Health News:Sen. Jeff Merkley Votes to Protect America's Kids From Tobacco 3Health News:Sen. Tom Harkin Votes to Protect America's Kids From Tobacco 2Health News:Sen. Tom Harkin Votes to Protect America's Kids From Tobacco 3Health News:Breast Cancer Patients May be Spared Additional Surgery 2Health News:Breast Cancer Patients May be Spared Additional Surgery 3Health News:Universal Health Services, Inc. Announces Marc D. Miller Named President of Universal Health Services 2Health News:Court Grants AstraZeneca Preliminary Injunction Against Apotex in PULMICORT RESPULES Patent Litigation 2
Straight shafts with 1 x 2 teeth and 5 mm tying platform. Serrated handle with dull finish....
Colibri style tips. Double toothed tips with 0.10 mm teeth spaced 1 mm apart and 7 mm tying platform. Wide serrated handle with polished finish....
Straight shafts with teeth and 6 mm crisscross serrated tying surfaces. Serrated handle with polished finish....
Serrated, 10 mm tips angled 30 degrees. Serrated cross action handle with polished finish....
Medicine Products: